Lawyer profile for UK 2022
Chambers Research is conducted by 200 Research Analysts, across 200 jurisdictions and provides nearly 6,000 rankings tables. Annually we collect hundreds of thousands of responses from clients, the majority via in-depth interview. Learn more about our methodology.
Life Sciences: Regulatory - UK-wide
Up and Coming
This content is provided by Sarah Cowlishaw
Sarah Cowlishaw supports innovative pharmaceutical, biotech, medical device, diagnostic and software technology companies on regulatory, compliance, transactional, and legislative matters. She is a co-chair of Covington’s multidisciplinary Digital Health Initiative, and regularly advises on legal issues presented by digital health technologies including artificial intelligence.
Sarah has played a pivotal role in negotiating supply arrangements for COVID-19 vaccines and non-vaccine COVID-19 related products, including before the European Commission and the UK Government.
She regularly advises the pharma and device industry on regulatory matters, including on borderline determinations, adverse event and other reporting obligations, manufacturing controls, and labeling and promotion. Sarah is also well equipped to advise clients on the new EU Medical Devices Regulation and In Vitro Diagnostic Medical Devices Regulation, and the new UK-specific regulatory regime for medical devices, introduced in January 2021.
On the commercial side, her experience covers the full range of agreements that span the product life-cycle in the life sciences sector. Notably she advised Illumina on its partnership with Genomics England, to sequence up to 500,000 whole genomes for the NHS Genomic Medicine Service. She also advised Sensyne Health on regulatory matters in connection with its £60 million IPO on London’s AIM market.